Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolios
Close

Neurobo Pharmaceuticals Inc (NRBO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Neurobo Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.6000 +0.3600    +8.49%
16/05 - Closed. Currency in USD ( Disclaimer )
Pre Market
4.6000
0.0000
0.0000%
8:47:09 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 55,863
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 4.1200 - 4.6310
Neurobo Pharmaceuticals 4.6000 +0.3600 +8.49%

Neurobo Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Neurobo Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

8

Equity Type

ORD

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Contact Information

Address 545 Concord Avenue Suite 210
Cambridge, 02138
United States
Phone 857 702 9600
Fax -

Top Executives

Name Age Since Title
Roy Lester Freeman 71 - Chairman of Scientific Advisory Board
Andrew I. Koven 66 2021 Independent Chairman of the Board
D. Gordon Strickland 77 2022 Independent Director
Michael H. Salsbury 74 2019 Independent Director
Jason L. Groves 53 2019 Independent Director
Hyung-Heon Kim 49 2021 CEO, President, Principal Executive & Director
Caroline M. Apovian - - Member of Scientific Advisory Board
Leigh Perreault - - Member of Scientific Advisory Board
Mark A. Glickman 58 2023 Independent Director
James Patrick Tursi 59 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NRBO Comments

Write your thoughts about Neurobo Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Johnny Hart
Johnny Hart Feb 12, 2024 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
love It
Tariq AlZadjali
Tariq AlZadjali Jul 20, 2021 8:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No financial report no earning ?!
Micheal ODriscoll
Micheal ODriscoll Jul 20, 2021 8:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this will be back down once the market opens
Kerem işcanoğlu
Kerem işcanoğlu Feb 01, 2021 10:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.directorstalkinterviews.com/neurobo-pharmaceuticals---consensus-indicates-potential-307.8-upside/412957382
Fl Fa
Fl Fa Jan 21, 2021 5:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
did they do a split? down from 250 to 5??
Eric Grant
Eric Grant Jan 21, 2021 5:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BOSTON, Sept. 12, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. ( Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company, announced today a 1-for-30 reverse split of its Common Stock, par value $0.001 ("common stock"), effective at 5:00 pm Eastern time today.
Cookie Crumbler
Cookie Crumbler May 12, 2020 6:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
how ridiculous is this - the stock is being traded at $ 13.81, but the ask price is $23.00 = Get real !!!
Mark Jo
Mark Jo May 12, 2020 6:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Because of low volume.
The Lost
The Lost Apr 22, 2020 5:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm going to gamble and load up on more at 13.92
The Lost
The Lost Feb 15, 2020 2:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm taking a ride for this one like I did with axsome therapeutics last year
The Lost
The Lost Dec 26, 2019 9:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
. 33
Robert Farias
Robert Farias Sep 07, 2018 7:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
They headimg back up?
Luc Apers
Luc Apers Jul 17, 2018 10:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thnx.. Today up again, that's the way we like it !
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email